We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
A successful management of refractory immune thrombocytopenic purpura with Eltrombopag during pregnancy complicated with superimposed preeclampsia.
- Authors
Miyashita, Dai; Sayama, Seisuke; Iriyama, Takayuki; Nakazaki, Kumi; Toshimitsu, Masatake; Seyama, Takahiro; Kumasawa, Keiichi; Nagamatsu, Takeshi; Kurokawa, Mineo; Osuga, Yutaka
- Abstract
Eltrombopag, a thrombopoietin receptor agonist, is approved for treating patients with immune thrombocytopenic purpura (ITP) refractory to corticosteroids and intravenous immunoglobulin (IVIg) therapy. We report a 32-years-old nulliparous Japanese woman with ITP and chronic hypertension who developed pulmonary edema due to superimposed preeclampsia at 27 weeks of gestation. She received therapy with corticosteroids, IVIg and Eltrombopag, but her platelet level was fluctuating and was difficult to achieve a well sustained response. A transient leukocytosis was noted but resolved by Eltrombopag dose reduction. Her pregnancy was complicated with preeclampsia with severe features required a prompt delivery. Although recent evidence supports the safety and efficacy of Eltrombopag use during pregnancy, unreported risks may underlie its use during pregnancy.
- Subjects
THROMBOPOIETIN receptor agonists; ELTROMBOPAG; PREECLAMPSIA; PREGNANCY; JAPANESE women
- Publication
Oxford Medical Case Reports, 2023, Vol 2023, Issue 5, p1
- ISSN
2053-8855
- Publication type
Article
- DOI
10.1093/omcr/omad047